Kyowa Hakko Bio Italia S.r.l.

Kyowa Hakko Bio is a global leader in biotechnology and fermentation technology, specializing in the development and manufacturing of high-quality amino acids, nucleic acid-related compounds, vitamins, organic acids, oligosaccharides, and dipeptides. The company serves pharmaceutical, nutrition, and healthcare markets worldwide with over 60 years of manufacturing expertise. Their extensive product portfolio includes ultra-pure amino acids, strategically branded ingredients like Cognizin citicoline and Immuse, pharmaceutical-grade and food-grade ingredients, and human milk oligosaccharides (HMOs). Kyowa employs leading-edge fermentation technology and biotechnology to create innovative manufacturing processes, with a primary objective to organically integrate fermentation and synthesis. The company has received FDA GRAS notices for their human milk oligosaccharides and operates manufacturing facilities globally including expanded citicoline production in Hofu, Japan. Their Kyowa Quality (KQ) brand represents an extensive line of ultra-pure amino acids backed by rigorous quality assurance. The company serves pharmaceutical companies requiring high-quality APIs and excipients, supplement and nutrition markets with life-enhancing benefits, cosmetic and personal care industries, and offers condition-specific branded ingredients for consumer health benefits. Recent partnerships include collaboration with Singapore's Agency for Science, Technology and Research (ASTAR) to study human milk oligosaccharides, demonstrating their commitment to advancing nutritional science and biotechnology innovation.